Abstract:Abstract Background The aberrant expression of endothelial cell specific molecule 1 (ESM1) is frequent in the carcinogenesis of various neoplasms. However, the expression profile, potential biological function and prognostic value of ESM1 in CSCC remain undetermined. Methods In the present study, we used human specimens to investigate the expression pattern of ESM1 in normal cervical tissue, LSIL, HSIL and CSCC samples by IHC assay and RT-qPCR. The expression pattern and the diagnostic or prognostic value of ESM1 were then further validated and explored in CSCC based on GEO and TCGA. Genomic enrichment analysis (GSEA) was applied to probe the masked molecular mechanisms of ESM1 in CSCC. Finally, the molecular mechanisms of ESM1 in human CSCC cell lines, including SiHa and ME-180 cells, were explored by in vitro studies of RNA interference experiments. Results In human samples, the ESM1 was significantly hyper-expressed in CSCC or HSIL, compared with LSIL or normal cervical tissue. The data from TCGA and GEO further confirmed that ESM1 was overexpressed in CSCC and was significantly related to dismal overall survival (OS) in CSCC patients. Furthermore, GSEA analysis showed that the CSCC patients with ESM1high were mostly enriched in angiogenesis and the VEGFα signaling pathway. Finally, the in vitro experiment suggested that interference of ESM1 inhibited the cell proliferation, migration, invasion and enhanced apoptosis, resulting in the reduction of VEGFα expression, HIF-1α expression, the phosphorylation of VEGFR2 (P-VEGFR2) and ERK-1/2 (P-ERK-1/2) in SiHa and ME-180 cells. Conclusion This assay figures out that ESM1 is notably overexpressed in CSCC patients. Overexpression of ESM1 predicts adverse prognosis of CSCC, and overexpressed ESM1, VEGFα and HIF-1α harbored synergistic effect in tumorigenesis and progression of CSCC cells through the VEGFα/VEGFR2/ERK signaling pathway. Thus, ESM1 and related genes may serve as promising diagnostic or prognostic biomarkers and candidate therapeutic targets for CSCC patients.

Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach

Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy

Endothelial cell specific molecule-1 and human cancer

Endocan: A New Marker for Cancer and a Target for Cancer Therapy.

Roles of endothelial cell specific molecule‐1 in tumor angiogenesis (Review)

Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.

Targeting ESM1/ VEGFα signaling axis: a promising therapeutic avenue for angiogenesis in cervical squamous cell carcinoma

Endothelin-1 and Its Role in Cancer and Potential Therapeutic Opportunities

A Promising New Cancer Marker: Long Noncoding RNA EGFR-AS1

Targeting CD147 is a Novel Strategy for Antitumor Therapy

Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity

Antibody Library-based Tumor Endothelial Cells Surface Proteomic Functional Screen Reveals Migration-stimulating Factor as an Anti-angiogenic Target

Angiogenesis-related Molecular Targets in Esophageal Cancer

Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer

ESM1/VEGFα signaling pathway augments endothelial cell proliferation and tumor angiogenesis in human cervical squamous cell carcinoma

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Endothelial cell-specific molecule 1 (ESM1) promoted by transcription factor SPI1 acts as an oncogene to modulate the malignant phenotype of endometrial cancer

The Eef1a Protein in Cancer: Clinical Significance, Oncogenic Mechanisms, and Targeted Therapeutic Strategies

ESM1/VEGFα/ERK signaling axis augments cell proliferation and tumor angiogenesis in human cervical squamous cell carcinoma

Inactivation of Endothelial ZEB1 Impedes Tumor Progression and Sensitizes Tumors to Conventional Therapies.

The role of ESM1 in the lipids metabolic reprogramming and angiogenesis of lung adenocarcinoma cells